Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
14047
Yamawaki K, Ishiguro T, Mori Y, Yoshihara K, Suda K, Tamura R, Yamaguchi M, Sekine M, Kashima K, Higuchi M, Fujii M, Okamoto K, Enomoto T.
Sox2-dependent inhibition of p21 is associated with poor prognosis of endometrial cancerCancer Sci
2017
108(4):632-640
PubMed ID: 28188685
DOI: 10.1111/cas.13196
14971
Tamura R, Yoshihara K, Yamawaki K, Suda K, Ishiguro T, Adachi S, Okuda S, Inoue I, Verhaak RG, Enomoto T.
Novel kinase fusion transcripts found in endometrial cancerSci Rep
2015
5:18657
PubMed ID: 26689674
DOI: 10.1038/srep18657
18132
Weigelt B, Warne PH, Lambros MB, Reis-Filho JS, Downward J.
PI3K pathway dependencies in endometrioid endometrial cancer cell linesClin Cancer Res
2013
19(13):3533-44
PubMed ID: 23674493
DOI: 10.1158/1078-0432.CCR-12-3815